<DOC>
	<DOCNO>NCT00001059</DOCNO>
	<brief_summary>To evaluate safety efficacy liposomal doxorubicin hydrochloride ( DOX-SL ) alone combination bleomycin vincristine long-term treatment AIDS-related Kaposi 's sarcoma . To determine whether 3-drug combination enhance progression-free survival quality life . Liposomal formulation chemotherapeutic agent increase drug accumulation tumor , permit disease palliation relatively low dos thus decrease dose-limiting toxicity . Multi-agent therapy consider effective single-agent therapy ; therefore , DOX-SL combine bleomycin vincristine .</brief_summary>
	<brief_title>Comparison Liposomal Doxorubicin Used Alone Combination With Bleomycin Plus Vincristine Treatment Kaposi 's Sarcoma Patients With AIDS</brief_title>
	<detailed_description>Liposomal formulation chemotherapeutic agent increase drug accumulation tumor , permit disease palliation relatively low dos thus decrease dose-limiting toxicity . Multi-agent therapy consider effective single-agent therapy ; therefore , DOX-SL combine bleomycin vincristine . Patients randomize receive intravenous DOX-SL alone combination vincristine/bleomycin every 2 week . Filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) may give need neutropenia . AS PER AMENDMENT 11/7/96 : Based interim review data , recommend subject receive DOX-SL plus vincristine/bleomycin vincristine/bleomycin discontinue receive DOX-SL alone unless , opinion treat physician , benefit DOX-SL plus vincristine/bleomycin regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : GCSF . Licensed Treatment INDapproved antiretrovirals ( AZT , ddI , ddC , d4T ) . PCP prophylaxis ( require CD4 count &lt; 200 cells/mm3 ) . Chemoprophylaxis maintenance bacterial infection , candidiasis , MAC , herpes simplex . Up 14 day metronidazole . Recombinant erythropoietin . Patients must : Documented HIV infection . Advanced stage Kaposi 's sarcoma . No active acute opportunistic infection . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Significant pulmonary insufficiency ( unless due pulmonary KS ) . Significant cardiac insufficiency . Other active malignancy except basal squamous cell carcinoma skin situ cervical cancer . Grade 2 bad peripheral neuropathy . Altered mental status prevents inform consent . Active Mycobacterium tuberculosis . Hypersensitivity allergic reaction study drug E. coliderived medication filgrastim ( GCSF ) . Concurrent Medication : Excluded : GMCSF . Drugs associate peripheral neuropathy ( approved antiretrovirals vincristine ) . Multidrug therapy active Mycobacterium tuberculosis ( although isoniazid pyridoxine allow treatment positive PPD , permission study chair ) . Concurrent Treatment : Excluded : Radiation therapy study marker lesion . Patients follow prior condition exclude : Neuropsychiatric history . Prior Medication : Excluded : Any antiKS therapy within 21 day prior study entry . Prior systemic therapy anthracycline ( include liposomal anthracyclines ) , vincristine , bleomycin . Any investigational drug ( available Treatment IND use FDAsanctioned purpose ) within 14 day prior study entry . PER AMENDMENT 11/29/95 : No 2 cycle systemic chemotherapy Kaposi 's sarcoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Vincristine</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Liposomes</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Bleomycin</keyword>
	<keyword>Drug Carriers</keyword>
</DOC>